Biotech Firm Omega Therapeutics Gets OK For Ch. 11 Plan

By Rick Archer · July 30, 2025, 2:27 PM EDT

A Delaware bankruptcy judge approved biotechnology developer Omega Therapeutics' Chapter 11 plan Wednesday, after no objections to the company's plan to distribute its remaining assets were raised at a brief hearing....

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Bankruptcy Scorecard

Summary

Biotechnology company Omega Therapeutics hit Chapter 11 in Delaware, listing over $140 million of debt on its petition and having filed a form with the U.S. Securities and Exchange Commission saying it had entered a restructuring agreement with an affiliate of its controlling stockholder.

Case Number

1:25-bk-10211

Judge

Brendan L. Shannon

Venue

U.S. Bankruptcy Court for the Northern District of Alabama

Capital Structure

Total Liabilities:

Over $140.4 million in debt

View Full Scorecard

Case Information

Case Title

OMGA Liquidating, Inc.

Case Number

1:25-bk-10211

Court

Delaware

Nature of Suit

Date Filed

February 10, 2025

Biotech Firm Omega Therapeutics Gets OK For Ch. 11 Plan

Bankruptcy Scorecard

Summary

Case Number

Judge

Venue

Capital Structure

Total Liabilities:

Related Sections

Case Information

Case Title

Case Number

Court

Nature of Suit

Date Filed

Recent Articles By Rick